KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Current Leases (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Current Leases for 3 consecutive years, with $317000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Leases fell 66.17% year-over-year to $317000.0, compared with a TTM value of $317000.0 through Dec 2025, down 66.17%, and an annual FY2025 reading of $317000.0, down 66.17% over the prior year.
  • Current Leases was $317000.0 for Q4 2025 at Biocryst Pharmaceuticals, down from $1.4 million in the prior quarter.
  • Across five years, Current Leases topped out at $2.5 million in Q1 2023 and bottomed at $317000.0 in Q4 2025.
  • Average Current Leases over 3 years is $1.4 million, with a median of $1.3 million recorded in 2024.
  • Peak annual rise in Current Leases hit 63.48% in 2025, while the deepest fall reached 66.17% in 2025.
  • Year by year, Current Leases stood at $1.6 million in 2023, then plummeted by 41.07% to $937000.0 in 2024, then tumbled by 66.17% to $317000.0 in 2025.
  • Business Quant data shows Current Leases for BCRX at $317000.0 in Q4 2025, $1.4 million in Q3 2025, and $1.8 million in Q1 2025.